Fagron NV (EBR:FAGR)

Belgium flag Belgium · Delayed Price · Currency is EUR
20.60
-0.05 (-0.24%)
Aug 8, 2025, 5:35 PM CET
-0.24%
Market Cap1.51B
Revenue (ttm)918.75M
Net Income (ttm)85.69M
Shares Out73.09M
EPS (ttm)1.17
PE Ratio17.61
Forward PE15.47
Dividend0.35 (1.69%)
Ex-Dividend DateMay 19, 2025
Volume41,822
Average Volume76,667
Open20.65
Previous Close20.65
Day's Range20.55 - 20.75
52-Week Range15.14 - 23.50
Beta0.25
RSI29.05
Earnings DateJul 31, 2025

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointest... [Read more]

Sector Healthcare
Founded 1990
Employees 3,828
Stock Exchange Euronext Brussels
Ticker Symbol FAGR
Full Company Profile

Financial Performance

In 2024, Fagron NV's revenue was 871.96 million, an increase of 14.28% compared to the previous year's 762.99 million. Earnings were 80.55 million, an increase of 14.18%.

Financial Statements

News

Fagron increases share capital through exercise subscription rights

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the ...

2 months ago - GlobeNewsWire

Record first-quarter revenue of €239 million, reflecting 14% topline growth

Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2025 – 7:00 AM CET Record first-quarter revenue of €239 million, reflecting 14% topline growth Fagron...

4 months ago - GlobeNewsWire

Fagron: FDA Warning Letter Creates New Entry Opportunity

Fagron: FDA Warning Letter Creates New Entry Opportunity

7 months ago - Seeking Alpha

Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook

Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 October 2024 – 7:00 AM CET Fagron reports outstanding third quarter 2024 performance with 12.1% revenue gro...

10 months ago - GlobeNewsWire

Record revenue of €209 million in first quarter reflecting 15% topline growth

Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagr...

1 year ago - GlobeNewsWire

Continued strong third quarter performance with 11% topline growth to €191 million

Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 October 2023 – 7:00 AM CET Continued strong third quarter performance with 11% topline growth to €191 milli...

1 year ago - GlobeNewsWire

Fagron NV (ARSUF) Q2 2023 Earnings Call Transcript

Fagron NV (OTC:ARSUF) Q2 2023 Earnings Conference Call August 3, 2023 3:30 AM ET Company Participants Karen Berg - Investor Relations Rafael Padilla - Chief Executive Officer Karin de Jong - Chief Fin...

2 years ago - Seeking Alpha